|7/12/2021||Orion recalls Multivita Forte dietary supplement from consumers|
|7/2/2021||Orion publishes Half-Year Financial Report for January–June 2021 on Monday 19 July 2021|
|6/21/2021||Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion|
|6/9/2021||Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy|
The Annual General Meeting of Orion Corporation was held on Thursday 25 March 2021 at Orion's Head Office in Espoo. The decisions and related material are available here.
|7/22/2021||Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)|
|7/21/2021||Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)|
|7/19/2021||Orion Group Half-Year Financial Report 1-6/2021|
|7/19/2021||Orion Corporation's financial reporting and Annual General Meeting in 2022|
Orion published Half-Year Financial Report for January–June 2021 on Monday, 19 July 2021. The report, related presentation material and link to the webcast recording are available here.
Orion Group's Financial Statement documents for 2020 are available here.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.